A comparative study evaluated tirzepatide and semaglutide for asthma outcomes, finding the difference between the two GLP-1-based drugs was smaller than anticipated. Both peptides showed potential benefits in asthma control, likely linked to weight loss and anti-inflammatory effects. The findings suggest either drug may help patients with obesity-related asthma.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.